

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on May 9, 2007

PATENT
Attorney Docket No.: 020093-004010US

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Marnix L. Bosch

Application No.: 10/538,226

Filed: June 6, 2005

For: ADMINISTRATION OF
DENDRITIC CELLS PARTIALLY
MATURED IN VITRO FOR THE
TREATMENT OF TUMORS

Confirmation No.: 9406

Examiner: Unassigned

Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner.

Copies of the references, in compliance with the requirements of 37 CFR §1.98(a)(2), are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the International Search report corresponding to the PCT application, as well as copy of the Supplementary Search Report corresponding to the co-pending European application.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Date: 9 May 2007

By: Brian W. Poor
Brian W. Poor
Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 206-467-9600
Fax: 206-623-6793
BWP:jms
61031531 v1

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/538,226
		Filing Date	June 6, 2005
		First Named Inventor	Bosch, Marnix L.
		Art Unit	1642
		Examiner Name	Unassigned
Sheet	1	of	3
		Attorney Docket Number	020093-004010US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,558,951	05-06-2003	Tomal et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AB	PCT	WO 00/47719		08-27-2000	Innovative Properties Company		<input type="checkbox"/>
	AC	PCT	WO 03/010292	A2	02-06-2003	Northwest Biotherapeutics, Inc.		<input type="checkbox"/>
	AD	PCT	WO 04/076651	A2	09-10-2004	Northwest Biotherapeutics, Inc.		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known Application Number 10/538,226 Filing Date June 6, 2005 First Named Inventor Bosch, Marnix L. Art Unit 1642 Examiner Name Unassigned Attorney Docket Number 020093-004010US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	AE	Candido <i>et al.</i> , "Local Administration of Dendritic Cells Inhibits Established Breast Tumor Growth: Implications for Apoptosis-inducing Agents," <i>Cancer Res.</i> 61:228-236 (2001).	<input type="checkbox"/>		
	AF	Chakraborty <i>et al.</i> , "Stimulatory and Inhibitory Differentiation of Human Myeloid Dendritic Cells," <i>Clin. Immunol.</i> 94:88-98 (1999).	<input type="checkbox"/>		
	AG	Kadowski <i>et al.</i> , "Distinct CpG DNA and Polyinosinic-Polycytidylic Acid Double-Stranded RNA, Respectively, Stimulate CD11c ⁺ Type 2 Dendritic Cell Precursors and CD11c ⁺ Dendritic Cells to Produce Type I IFN ¹ ," <i>J. Immunol.</i> 166:2291-2295 (2001).	<input type="checkbox"/>		
	AH	Kikuchi <i>et al.</i> , "Dendritic Cells Modified to Express CD40 Ligand Elicit Therapeutic Immunity Against Preexisting Murine Tumors," <i>Blood</i> 96:91-99 (2000).	<input type="checkbox"/>		
	AI	Kurts <i>et al.</i> , "Constitutive Class I-restricted Exogenous Presentation of Self Antigens In Vivo," <i>J. Exp. Med.</i> 184:923-930 (1996).	<input type="checkbox"/>		
	AJ	Kurts <i>et al.</i> , "Class I-restricted Cross-Presentation of Exogenous Self-Antigens Leads to Deletion of Autoreactive CD8 ⁺ T Cells," <i>J. Exp. Med.</i> 186:239-245 (1997).	<input type="checkbox"/>		
	AK	Lanzavecchia, "Dendritic Cell Maturation and Generation of Immune Responses," <i>Haematologica</i> 84:(EHA- 4 educational book):23-25 (1999).	<input type="checkbox"/>		
	AL	Melero <i>et al.</i> , "Intratumoral Injection of Bone-Marrow Derived Dendritic Cells Engineered to Produce Interleukin-12 Induces Complete Regression of Established Murine Transplantable Colon Adenocarcinomas," <i>Gene Therapy</i> 6:1779-1784 (1999).	<input type="checkbox"/>		
	AM	Nestle, "Dendritic Cell Vaccination for Cancer Therapy," <i>Oncogene</i> 19:6673-6679 (2000).	<input type="checkbox"/>		
	AN	Nikitina and Gabrilovich, "Combination of γ -Irradiation and Dendritic Cell Administration Induces a Potent Antitumor Response in Tumor-bearing Mice: Approach to Treatment of Advanced Stage Cancer," <i>Int. J. Cancer</i> 94:825-833 (2001).	<input type="checkbox"/>		
Examiner Signature				Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known Application Number 10/538,226 Filing Date June 6, 2005 First Named Inventor Bosch, Marnix L. Art Unit 1642 Examiner Name Unassigned Attorney Docket Number 020093-004010US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. †	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	AO	Nishioka <i>et al.</i> , "Induction of Systemic and Therapeutic Antitumor Immunity Using Intratumoral Injection of Dendritic Cells Genetically Modified to Express Interleukin 12," <i>Cancer Res.</i> 59:4035-4041 (1999).	<input type="checkbox"/>	
	AP	Shortman and Heath, "Immunity or Tolerance? That is the Auestion for Dendritic Cells," <i>Nature Immunol.</i> 2:988-989 (2001).	<input type="checkbox"/>	
	AQ	Tanaka <i>et al.</i> , "Intratumoral Injection of Dendritic Cells After Treatment of Anticancer Drugs Induces Tumor-specific Antitumor Effect <i>In Vivo</i> ," <i>Int. J. Cancer</i> 101:265-269 (2002).	<input type="checkbox"/>	
	AR	Tjoa <i>et al.</i> , "Dendritic Cell-Based Immunotherapy for Prostate Cancer," <i>CA-A Cancer J. Clinic.</i> 49:117-128 (1999).	<input type="checkbox"/>	
	AS	Tong <i>et al.</i> , "Combined Intratumoral Injection of Bone Marrow-derived Dendritic Cells and Systemic Chemotherapy to Treat Pre-existing Murine Tumors," <i>Cancer Res.</i> 61:7530-7535 (2001).	<input type="checkbox"/>	
	AT	Trimble <i>et al.</i> , "Maturation of Dendritic Cells for Cancer Immunotherapy, Using Inactivated BCG and Interferon Gamma: Induction of a Vigorous Th1 Response," <i>Proc. Am. Assoc. Cancer Res. Ann. Mtg.</i> , Abstract #3368, 43:680, XP001208099 (2002).	<input type="checkbox"/>	
	AU	Trionzi <i>et al.</i> , "Intratumoral Injection of Dendritic Cells Derived In Vitro in Patients with Metastatic Cancer," <i>Cancer</i> 89:2646-2654 (2000).	<input type="checkbox"/>	
	AV	Tsuji <i>et al.</i> , "Maturation of Human Dendritic Cells by Cell Wall Skeleton of <i>Mycobacterium bovis</i> Bacillus Calmette-Guerin: Involvement of Toll-Like Receptors," <i>Infect. Immun.</i> 68:6883-6890 (2000).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.